What is the Fiscal Year for Provectus Biopharmaceuticals?
Date: November 13, 2026
Provectus Biopharmaceuticals's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q2, which ends on June 30, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q2
Current Quarter End
June 30, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Knoxville, Tennessee, United States
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
PVCT
Website
https://provectusbio.comDescription
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Provectus Biopharmaceuticals and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.